NEW YORK, Aug 14 – Exelixis of South San Francisco, Calif., has announced an agreement with Elan Pharmaceuticals to develop a compound library, marking Exelixis’ initial chemistry deal.

“This is our first chemistry-focused collaboration and it validates the quality of the discovery organization, while offsetting some of the cost of building our large high throughput screening compound library for drug discovery at Exelixis,” George Scangos, Exelixis’s CEO, said in a statement released Monday.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.